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After a successful intervention, what more can we do to protect them from their underlying disease? Summary: This report presented 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) trial. In the trial, 699 high-risk patients with severe aortic stenosis were randomised to undergo either surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). At 5 years, the risk of death was 67.8% in the TAVR group and 62.4% in the SAVR group (hazard ratio 1.04; p=NS). There was no structural valve deterioration requiring surgical valve replacement in either group. Moderate or severe aortic regurgitation occurred in 14% of patients in the TAVR group and 1% of patients in the SAVR group (p<0.0001), and was associated with increased 5-year risk of mortality in the TAVR group (72.4% in patients with moderate or severe aortic regurgitation compared with 56.6% in patients with mild aortic regurgitation or less; p=0.003).
Comment: There has been concern as to the durability of valves implanted with TAVR compared to surgically. This 5-year analysis of the PARTNER trial should give us confidence that the Edwards Sapien valve will last at least that long, but it also showed that there was increased risk of aortic insufficiency with TAVR, and that this was associated with worse outcomes. There have been considerable improvements in the valves and implantation techniques since this early study, so this problem has substantially decreased over time.
Reference: Lancet 2015;385(9986):2477-2484 Abstract
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6-or 24-month duration of dual-antiplatelet therapy after stent implantation Authors: Costa F et al.
Summary:
This sub-analysis of the PRODIGY trial investigated the impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6-or 24-month DAPT after stent implantation. In PRODIGY, 1465 patients with ACS and 505 with stable CAD were randomised to 6-or 24-month DAPT. At 24 months, the composite of death, MI, or cerebrovascular accident (CVA) did not differ between the long-and short-term DAPT arms in either ACS or stable CAD patients. Long-term DAPT was associated with a 75% increase in Bleeding Academic Research Consortium (BARC)-class 2, 3, or 5 bleeding in ACS patients (hazard ratio 1.75; p=0.015) and a 5-fold increase in stable CAD patients (hazard ratio, 5.37; p=0.002). As a result, net adverse cardiovascular events (death, MI, CVA, BARC class 2, 3, or 5 bleeding) were more than doubled in stable CAD patients receiving 24-month DAPT, whereas they did not differ in ACS patients.
Comment: There is ongoing debate about the duration of DAPT after stent implantation. The PRODIGY study and several other small trials have suggested that 6 months is enough, but the DAPT and PEGASUS studies suggest that there is benefit from a longer duration. This sub-analysis of PRODIGY shows that prolonged therapy may be more beneficial in patients who have had stenting for an ACS rather than for stable disease. In the DAPT study there was less stent thrombosis and MI in the non ACS stented patients (75% of subjects) but more bleeding and death in this group. These studies thus suggest that the benefits of prolonged DAPT in non ACS stented patients are not as great as when stents are implanted for ACS, and that a shorter duration could be considered.
POST-MI PATIENTS REMAIN AT HIGH AND PERSISTENT RISK 1-4
After a successful intervention, what more can we do to protect them from their underlying disease? Summary: This study examined the clinical utility of 7 more-sensitive cardiac troponin (cTn) assays in patients with renal dysfunction presenting with symptoms suggestive of AMI. 2813 patients who presented with chest pain (16% with renal dysfunction) were included. In patients with renal dysfunction and elevated baseline cTn levels (≥99th percentile), AMI was the most common diagnosis for all assays (range 45%-80%). Diagnostic accuracy in patients with renal dysfunction (quantified by the area under the receiver-operator characteristic curve [AUC]) was 0.87-0.89 at presentation and increased to 0.91-0.95 at 3 hours, with no significant differences between the 7 cTn assays. Overall, the AUC in patients with renal dysfunction was only slightly lower than in patients with normal renal function. The optimal AUC-derived cTn cut-off levels in patients with renal dysfunction were significantly higher than those in patients with normal renal function.
Comment: It is sometimes difficult to determine if a troponin rise in the setting of chest pain with renal impairment is due to ACS or due to decreased excretion. This study shows that high-sensitivity troponin is still accurate for the diagnosis of MI in this context, but suggests that higher cut-offs should be considered for patients with renal dysfunction, although this would have to be formally tested before it could be adopted. : Circulation 2015; 131:2041 131: -2050 Comparison of clinical efficacy and cost of a cardiac imaging strategy versus a traditional exercise test strategy for the investigation of patients with suspected stable coronary artery disease Authors: Demire O et al.
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Summary:
This study compared the use of a cardiac imaging strategy and a traditional exercise test strategy for the investigation of patients with suspected stable CAD. Data for patients seen in rapid access chest pain clinics at 2 UK hospitals over a 12-month period were reviewed. Hospital A investigated 483 patients using an exercise tolerance test (ETT) and hospital B investigated 295 patients using a cardiac imaging test. Based on the findings of the ETT, hospital A performed invasive coronary angiography (ICA) in 127 (26.3%) patients, and 52 (40.9%) were found to have obstructive CAD. Based on cardiac imaging results, hospital B performed 63 ICAs (21.4% of population) and 32 (50.8%) had obstructive CAD. The average cost per patient was higher in hospital A than hospital B ($US875 vs $US750; p<0.001).
Comment: This study supports an early imaging strategy (CTCA, stress echo or nuclear) in the diagnosis of symptomatic CAD, and suggests this leads to more accurate diagnosis, less invasive procedures and lower costs. Many hospitals in Australia have adopted this strategy already, so it is reassuring to see that there is now some evidence to support this practice.
Reference: Am J Cardiol 2015; 115(12):1631 -1635 Abstract
